Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors

Myasthenia Gravis in Patients Treated With Immune Checkpoint Inhibitors

Background: Immune checkpoint inhibitors (ICIs) have improved outcomes significantly for patients across multiple tumor types, and now are being used in combination with other therapies and in earlier settings where treatment intent is curative. Immune-related adverse events occur commonly and there...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdulrahman Alghabban, MD, Lucy Corke, MD, Hans Katzberg, MD, Vera Bril, MD, Carolina Barnett-Tapia, MD, Warren Mason, MD, Raed Alothman, MD, Abdul Razak Albiruni Ryan, MD, David Hogg, MD, Srikala Sridhar, MD, Neesha Dhani, MD, Anna Spreafico, MD, Lawson Eng, MD, Adrian Sacher, MD, Penelope Bradbury, MD, Geoffrey Liu, MD, Natasha Leighl, MD, Frances A. Shepherd, MD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:JTO Clinical and Research Reports
Subjects:
Myasthenia gravis
Immune checkpoint inhibitors
Immune-related neurotoxicity
Myositis-myocarditis overlap
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001425
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Immune checkpoint inhibitors (ICIs) have improved outcomes significantly for patients across multiple tumor types, and now are being used in combination with other therapies and in earlier settings where treatment intent is curative. Immune-related adverse events occur commonly and there are clear guidelines regarding management. Neurological toxicities such as myasthenia gravis (MG) with or without myositis are rare but are associated with high morbidity and mortality. Methods: This single-centre study presents a series of patients treated with ICIs who subsequently developed immune-related MG. Presenting symptoms, treatments and outcomes were abstracted from retrospective chart review. Results: We identified 16 patients (9 thoracic malignancies, 7 other tumor sites) who were diagnosed with MG after one or more cycles of ICI. Eleven had overlapping myositis. The median time from the first ICI treatment to the onset of symptoms was 49 days (range 17–361). All patients received steroids (prednisone 1–2 mg/kg); six required other immunosuppressive agents, and five underwent plasma exchange. Only two patients had complete resolution, eight improved with residual symptoms, two experienced initial improvement followed by deterioration, and four worsened despite treatment. Six patients died as a result of myasthenia-related complications (38%), three from progressive cancer (19%) and seven remain alive at the time of review (44%). Conclusion: ICI-related MG is a rare and potentially fatal adverse event. Diagnosis and management remain a challenge, especially with negative serological markers and in the presence of overlapping syndromes with high mortality rates. Prompt recognition and multimodality treatment are key. Clinicians should have a low threshold for diagnosis and early management.
ISSN:2666-3643

Similar Items